UNIGE document Privat-docent Thesis
previous document  unige:106351  next document
add to browser collection

Life cycle of a drug – a perspective for policy makers

Defense Thèse de privat-docent : Univ. Genève, 2018
Abstract The interest in pharmaceutical agents is shared by key players pursuing the same general objective: to discover, test and treat patients. In this race, the pharmaceutical industries, regulatory bodies, physicians, patients, payers have various motivations, incentives and conflicting interests. As in most industrialised countries, Switzerland is expected to provide the best medicines to the largest number of patients using a limited budget, leaving the country struggling to reach a compromise between drug companies' profit maximization and authorities' cost containment issues. This thesis aims to describe the life cycle of a drug to give the reader a deeper knowledge of the key elements, different perspectives, and winning strategies that policy makers face when making highly valuable decisions.
Keywords Life cycle of a drugPolicy makersPatentMarket accessPricing modelsPersonal importation schemeEvergreening stratégiesSpillover effect
Full text
Thesis (3.4 MB) - document accessible for UNIGE members only Limited access to UNIGE
(ISO format)
VERNAZ-HEGI, Nathalie. Life cycle of a drug – a perspective for policy makers. Université de Genève. Thèse de privat-docent, 2018. doi: 10.13097/archive-ouverte/unige:106351 https://archive-ouverte.unige.ch/unige:106351

569 hits



Deposited on : 2018-07-10

Export document
Format :
Citation style :